The Drug-Induced Respiratory Disease Website and App

Tofacitinib

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (interstitial lung disease/ILD)

XLVI - Pulmonary vasculopathy

XLVI.b

Pulmonary arterial hypertension

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.u

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

LIX - Infections & related conditions

LIX.b

Opportunistic pulmonary/systemic infections

LIX.e

Pneumocystis jiroveci pneumonia

LIX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX.h

Nontuberculous pulmonary mycobacterial infection/superinfection

LIX.q

Viral pneumonia

LIX.x

Cryptococcus pulmonary and/or systemic infection

LIX.y

Histoplamosis (reactivation)